For biotechs in the industry’s handful of hot areas, it’s a seller’s market

Max Gelman

Senior Editor

A radiopharma company purchased for more than three times the price of its IPO from a few months earlier. Neuroscience companies driving up their offers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For biotechs in the industry’s handful of hot areas, it’s a seller’s market

Max Gelman

Senior Editor

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?

For biotechs in the in­dus­try’s hand­ful of hot ar­eas, it’s a sell­er’s mar­ket

Max Gelman

Senior Editor

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

For biotechs in the industry’s handful of hot areas, it’s a seller’s market

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Are programs with compounded GLP-1s safe for your population?